CR20220041A - Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab - Google Patents

Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Info

Publication number
CR20220041A
CR20220041A CR20220041A CR20220041A CR20220041A CR 20220041 A CR20220041 A CR 20220041A CR 20220041 A CR20220041 A CR 20220041A CR 20220041 A CR20220041 A CR 20220041A CR 20220041 A CR20220041 A CR 20220041A
Authority
CR
Costa Rica
Prior art keywords
antibody
crovalimab
dose
dosage
administration
Prior art date
Application number
CR20220041A
Other languages
English (en)
Inventor
Antoine Soubret
Alexandre Antoine Bernard Sostelly
Félix Grégoire Jason Jaminion
Christoph Bucher
Jean-Eric Charoin
Simon Bertrand Marie Buatois
Gregor Jordan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220041A publication Critical patent/CR20220041A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con una dosis y régimen de administración de anticuerpos anti-C5, particularmente del anticuerpo anti-C5 Crovalimab, para usarse en un método de tratamiento o prevenir la enfermedad relacionada con C5 en un sujeto, que incluye hemoglobinuria nocturna paroxismal (PNH). El régimen de dosificación y tratamiento de la presente invención incluye la administración de un anticuerpo anti-C5, preferiblemente del anticuerpo anti-C5 Crovalimab, con dosis de carga seguido por la administración de (a) dosis de mantenimiento(s) del anticuerpo anti-C5 al sujeto, donde la dosis de carga administrada inicialmente es proporcionada intravenosamente al sujeto y la carga restante y las dosis de mantenimiento se administran subcutáneamente en una dosis baja como la dosis de carga administrada intravenosamente.
CR20220041A 2019-07-31 2020-07-30 Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab CR20220041A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19189442 2019-07-31
EP20174790 2020-05-14
EP20179591 2020-06-11
PCT/EP2020/071555 WO2021019036A1 (en) 2019-07-31 2020-07-30 Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
CR20220041A true CR20220041A (es) 2022-03-02

Family

ID=71846415

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220041A CR20220041A (es) 2019-07-31 2020-07-30 Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Country Status (12)

Country Link
US (1) US20220275070A1 (es)
EP (1) EP4003409A1 (es)
JP (2) JP7437261B2 (es)
KR (2) KR20210016333A (es)
CN (2) CN115068604A (es)
AU (1) AU2020322165A1 (es)
CA (1) CA3144923A1 (es)
CR (1) CR20220041A (es)
IL (1) IL288600B1 (es)
MX (1) MX2022001154A (es)
TW (1) TWI886140B (es)
WO (1) WO2021019036A1 (es)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
BRPI0211953B8 (pt) 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
CN107207607B (zh) * 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
IL259256B2 (en) 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
EP3408291A1 (en) 2016-01-25 2018-12-05 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
EP3554543A4 (en) * 2016-12-16 2020-09-02 Samsung Bioepis Co., Ltd. STABLE Aqueous ANTI-C5 ANTIBODY COMPOSITION
IL307593A (en) 2017-01-31 2023-12-01 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CA3080187A1 (en) * 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)

Also Published As

Publication number Publication date
CA3144923A1 (en) 2021-02-04
CN115068604A (zh) 2022-09-20
IL288600A (en) 2022-02-01
JP7437261B2 (ja) 2024-02-22
EP4003409A1 (en) 2022-06-01
TWI886140B (zh) 2025-06-11
CN114929273A (zh) 2022-08-19
TW202120125A (zh) 2021-06-01
MX2022001154A (es) 2022-02-22
AU2020322165A1 (en) 2022-01-06
IL288600B1 (en) 2026-02-01
JP2021038198A (ja) 2021-03-11
KR20210016333A (ko) 2021-02-15
WO2021019036A1 (en) 2021-02-04
KR20240033090A (ko) 2024-03-12
US20220275070A1 (en) 2022-09-01
JP2022101535A (ja) 2022-07-06
JP7748311B2 (ja) 2025-10-02

Similar Documents

Publication Publication Date Title
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
CO2021006290A2 (es) Dosificación subcutánea y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh)
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2019012884A (es) Terapia de combinacion.
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX376077B (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CR20220040A (es) Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
MX2022003610A (es) Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
CL2025003511A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
CR20220041A (es) Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
PE20240777A1 (es) Proteinas actrii y usos de las mismas
MX2023004017A (es) Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.
MX2021013248A (es) Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen.
CL2024001324A1 (es) Reducción del corticosteriode en el tratamiento con anticuerpos anti-cd38.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)